Mecide Gharibo

1.5k total citations
34 papers, 400 citations indexed

About

Mecide Gharibo is a scholar working on Oncology, Pathology and Forensic Medicine and Hematology. According to data from OpenAlex, Mecide Gharibo has authored 34 papers receiving a total of 400 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 14 papers in Pathology and Forensic Medicine and 14 papers in Hematology. Recurrent topics in Mecide Gharibo's work include Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Multiple Myeloma Research and Treatments (8 papers). Mecide Gharibo is often cited by papers focused on Lymphoma Diagnosis and Treatment (14 papers), Chronic Lymphocytic Leukemia Research (12 papers) and Multiple Myeloma Research and Treatments (8 papers). Mecide Gharibo collaborates with scholars based in United States, Germany and United Kingdom. Mecide Gharibo's co-authors include Asher Chanan‐Khan, Sundar Jagannath, Robert Vescio, Taimur Sher, Elizabeth Poplin, Kevin R. Kelly, Dale Schaar, Sikander Ailawadhi, Jeffrey Wolf and Roger Strair and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Mecide Gharibo

32 papers receiving 395 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mecide Gharibo United States 12 197 175 146 71 67 34 400
Geraldine Ferron‐Brady United States 11 209 1.1× 322 1.8× 210 1.4× 39 0.5× 72 1.1× 34 577
Robert H. Gersh United States 7 151 0.8× 190 1.1× 206 1.4× 48 0.7× 29 0.4× 8 501
Normann Steiner Austria 14 191 1.0× 219 1.3× 180 1.2× 108 1.5× 16 0.2× 55 471
Sara Gandolfi United States 10 172 0.9× 328 1.9× 247 1.7× 66 0.9× 19 0.3× 28 491
William Larry Gluck United States 8 172 0.9× 111 0.6× 66 0.5× 94 1.3× 52 0.8× 24 409
Koshi Akahane Japan 14 217 1.1× 301 1.7× 181 1.2× 40 0.6× 28 0.4× 63 658
Honghui Huang China 14 123 0.6× 183 1.0× 76 0.5× 114 1.6× 54 0.8× 37 471
Łukasz Bołkuń Poland 14 160 0.8× 187 1.1× 181 1.2× 78 1.1× 24 0.4× 52 510
Ellen Ingalla United States 5 126 0.6× 241 1.4× 127 0.9× 49 0.7× 27 0.4× 12 339
Xiaoying Qi China 13 183 0.9× 346 2.0× 311 2.1× 44 0.6× 24 0.4× 31 515

Countries citing papers authored by Mecide Gharibo

Since Specialization
Citations

This map shows the geographic impact of Mecide Gharibo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mecide Gharibo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mecide Gharibo more than expected).

Fields of papers citing papers by Mecide Gharibo

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mecide Gharibo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mecide Gharibo. The network helps show where Mecide Gharibo may publish in the future.

Co-authorship network of co-authors of Mecide Gharibo

This figure shows the co-authorship network connecting the top 25 collaborators of Mecide Gharibo. A scholar is included among the top collaborators of Mecide Gharibo based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mecide Gharibo. Mecide Gharibo is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Winter, Allison, Alex F. Herrera, Chaitanya Iragavarapu, et al.. (2024). Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR).. Journal of Clinical Oncology. 42(16_suppl). 7010–7010. 3 indexed citations
2.
Caimi, Paolo F., Stephen J. Schuster, Loretta J. Nastoupil, et al.. (2024). Outcomes in Patients (pts) with R/R Large B-Cell Lymphoma (LBCL) Who Received Nonconforming Product (NCP) to Commercial Release of Lisocabtagene Maraleucel (liso-cel) in the United States (US). Transplantation and Cellular Therapy. 30(2). S188–S189.
3.
4.
Lansigan, Frederick, David Andorsky, Morton Coleman, et al.. (2021). Completed Induction Phase Analysis of Magnify: Phase 3b Study of Lenalidomide + Rituximab (R 2) Followed By Maintenance in Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. Blood. 138(Supplement 1). 812–812. 11 indexed citations
5.
Sharman, Jeffrey P., Jason M. Melear, Abdulraheem Yacoub, et al.. (2021). INDUCTION R2 FOLLOWED BY MAINTENANCE IN PATIENTS WITH RELAPSED/REFRACTORY MANTLE CELL LYMPHOMA: INTERIM ANALYSIS FROM THE PHASE 3B MAGNIFY STUDY. Hematological Oncology. 39(S2). 1 indexed citations
6.
Andorsky, David, Morton Coleman, Abdulraheem Yacoub, et al.. (2020). MAGNIFY phase IIIb interim analysis of induction R2 followed by maintenance in relapsed/refractory indolent NHL.. Journal of Clinical Oncology. 38(15_suppl). 8046–8046. 8 indexed citations
7.
Coleman, Morton, David Andorsky, Abdulraheem Yacoub, et al.. (2020). Patients with Relapsed/Refractory Marginal Zone Lymphoma in the MAGNIFY Phase IIIb Interim Analysis of Induction R2 Followed By Maintenance. Blood. 136(Supplement 1). 24–25. 4 indexed citations
8.
Sharman, Jeff P., Kim Cocks, Chadi Nabhan, et al.. (2020). Longitudinal health‐related quality of life in first‐line treated patients with chronic lymphocytic leukemia: Results from the Connect® CLL Registry. SHILAP Revista de lepidopterología. 1(1). 188–198. 3 indexed citations
9.
Zichlin, Miriam L., et al.. (2019). A Budget Impact Analysis of the Introduction of Copanlisib for Treatment of Relapsed Follicular Lymphoma in the United States. Journal of Managed Care & Specialty Pharmacy. 25(4). 437–446. 9 indexed citations
10.
Ailawadhi, Sikander, Kevin R. Kelly, Robert Vescio, et al.. (2018). A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD–56-positive Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 19(1). 29–34. 57 indexed citations
11.
Cavenagh, Jamie, Heather Oakervee, Faith E. Davies, et al.. (2017). A phase I/II study of KW-2478, an Hsp90 inhibitor, in combination with bortezomib in patients with relapsed/refractory multiple myeloma. British Journal of Cancer. 117(9). 1295–1302. 42 indexed citations
12.
13.
14.
Levitt, Martin, Mecide Gharibo, Roger Strair, et al.. (2009). Accelerated R-COP: A Pilot Study for the Treatment of Advanced Low Grade Lymphomas that Has a High Complete Response Rate. Journal of Chemotherapy. 21(4). 434–438. 2 indexed citations
15.
Chanan‐Khan, Asher, Jeffrey L. Wolf, Mecide Gharibo, et al.. (2009). Phase I Study of IMGN901, Used as Monotherapy, in Patients with Heavily Pre-Treated CD56-Positive Multiple Myeloma - A Preliminary Safety and Efficacy Analysis.. Blood. 114(22). 2883–2883. 17 indexed citations
16.
Gharibo, Mecide, et al.. (2008). A Phase II Trial of Imatinib Mesylate in Patients With Metastatic Pancreatic Cancer. Pancreas. 36(4). 341–345. 20 indexed citations
17.
Saraiya, Biren, Murugesan Gounder, Jayeeta Dutta, et al.. (2008). Sequential topoisomerase targeting and analysis of mechanisms of resistance to topotecan in patients with acute myelogenous leukemia. Anti-Cancer Drugs. 19(4). 411–420. 16 indexed citations
18.
Medina, Daniel, Mecide Gharibo, Philip Savage, et al.. (2008). A Pilot study of allogeneic cellular therapy for patients with advanced hematologic malignancies. Leukemia Research. 32(12). 1842–1848. 12 indexed citations
19.
Chanan‐Khan, Asher, Mecide Gharibo, Sundar Jagannath, et al.. (2008). Phase I Study of IMGN901 in Patients with Relapsed and Relapsed/Refractory CD56-Positive Multiple Myeloma. Blood. 112(11). 3689–3689. 8 indexed citations
20.
Lin, Yong, Mecide Gharibo, Murugesan Gounder, et al.. (2007). Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors. Clinical Cancer Research. 13(19). 5876–5882. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Geraldine Ferron‐Brady Breakdown of academic impact, for papers by Robert H. Gersh Breakdown of academic impact, for papers by Normann Steiner Breakdown of academic impact, for papers by Sara Gandolfi Breakdown of academic impact, for papers by William Larry Gluck Breakdown of academic impact, for papers by Koshi Akahane Breakdown of academic impact, for papers by Honghui Huang Breakdown of academic impact, for papers by Łukasz Bołkuń Breakdown of academic impact, for papers by Ellen Ingalla Breakdown of academic impact, for papers by Xiaoying Qi
Rankless by CCL
2026